IntellectSky

Soumya's words,  Hello friends Hope all are keeping well. I know today's post would be bit lengthy but please bear with it as its necessary for those who feel COVID is just a common flu. - ME AND MY BATTLE WITH CORONA- I have written it as battle with CORONA because the fight with CORONA is in no way less than any of the historic battles.....but the only difference between this battle and those battles is that there they fought against a visible enemy knowing their each move and plans but here I had to fight against an invisible enemy without having least knowledge of its plans and moves. So the battle started on 22 nd April 2021. I got mild symptoms of COVID and being a responsible citizen immediately isolated myself from my family, got my RTPCR done. After 2 days got my reports and it was NEGATIVE. There was no limit of my happiness, the feeling that " yes I am away from the cruel clutches of CORONA" . But little did I know that this was just my illusion. T...

  On 3 rd May 2021, NATCO Pharma Limited has received Emergency Use approval for Baricitinib tablets, 1mg, 2mg and 4mg strengths from Central Drugs Standard Control Organization (CDSCO) in India. Baricitinib in combination with Remdesivir, is used for treatment of COVID-19 positive patients. Summary: In light of the grave and life threatening public health emergency, NATCO Pharma moved before the Controller of Patents for Compulsory License of Drug Baricitinib in India. NATCO seeking the Compulsory License under Section 92(1) with Section 92(3) of The Patents Act, 1970. Facts & Targeted Approach: PATENT: IN270765 (INCYTE/Lilly: Expiry Date: Mar 10, 2029) Patent Covers: Baricitinib Compound & its phosphoric acid salt. CDSCO Approvals: ·          May 07, 2018: For the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more d...